DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Different Doses of Vitamin A and Childhood Morbidity and Mortality

Information source: Bandim Health Project
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Mortality; Morbidity

Intervention: Vitamin A (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Bandim Health Project

Official(s) and/or principal investigator(s):
Peter Aaby, DMSc, Principal Investigator, Affiliation: Bandim Health Project

Summary

Vitamin A supplementation reduces all-cause mortality. It is therefore given with oral polio vaccine in national campaigns. However, it is not clear which dose is optimal. The two studies that have investigated the impact of different doses of vitamin A have both found that a smaller dose was better than a large dose. We therefore investigated if a smaller dose given with oral polio vaccine gives equal or better effect.

Clinical Details

Official title: Randomised Study of the Impact of Different Doses of Vitamin A on Childhood Morbidity and Mortality

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome:

Mortality

Hospitalisations

Morbidity

Growth

Secondary outcome: Rotavirus infection

Detailed description: Vitamin A supplementation (VAS) to children above 6 months of age reduces all-cause mortality with 23 %1 to 30 % in low-income countries. WHO recommends VAS at vaccination contacts. The currently recommended doses to be administered every 3-6 months are 100,000 IU for infants between 6 and 11 months of age and 200,000 IU for children 12 months and older. There is no clear evidence that a large dose is better than a small dose, the tendency being the opposite in the two studies of different doses of VAS that have been published so far. With the global effort to eradicate polio, national immunization days with oral polio vaccine (OPV) offer an additional opportunity to provide vitamin A. In Guinea-Bissau, a combined OPV and VAS campaign took place in November 2002. Given the uncertainty about the best dose of VAS, we aimed to examine whether the dose of vitamin A currently recommended by WHO or half this dose gives a better protection against childhood morbidity and mortality.

Eligibility

Minimum age: 6 Months. Maximum age: 5 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: Between 6 mo and 5 years old and thus eligible for OPV and vitamin A during national immunisation day

-

Exclusion Criteria: Children with overt signs of vitamin A deficiency will not be enrolled

in the study, but treated according to the recommendations. -

Locations and Contacts

Bandim Health Project, Apartado 861, Bissau, Guinea-Bissau
Additional Information

Starting date: November 2002
Last updated: September 12, 2005

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017